Invion Stock

Invion Rule of 40

Rule of 40 of Invion (IVX.AX) as of Sep 4, 2026.

Rule of 40

0.00

Last updated:

Rule of 40 of Invion is 2026 0.00 . Rule of 40 of Invion was 2025 -155.84 % . It decreases by % higher compared to the previous year.

The Invion Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2015
-5,875.13 AUD
Jan 1, 2016
-2,618.91 AUD
Jan 1, 2019
361.40 AUD
Jan 1, 2020
-39.96 AUD
Jan 1, 2021
-100.46 AUD
Jan 1, 2022
-29.25 AUD
Jan 1, 2023
-14.65 AUD
Jan 1, 2024
-155.84 AUD
The Invion Rule of 40 history
YEARRule of 40YoY
-155.84 %+964.07%
-14.65 %-49.93%
-29.25 %-70.89%
-100.46 %+151.37%
-39.96 %-111.06%
361.40 %-113.80%
-2,618.91 %-55.42%
-5,875.13 %
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of Rule of 40 Invion since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

Quality — Invion

All Key Metrics — Invion